Clinical trial · Interventional
Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy
NCT01000246CI-TRIAL-00002912RIFLUVACcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients treated with chemotherapy or immunosuppressives are at higher risk of influenza infection and mortality and morbidity are higher compared to healthy adults. Vaccination against the influenza virus can prevent these complications. In this study it is investigated whether vaccination during chemotherapy is effective in reaching protective serum antibody concentrations and the relation between time of vaccination (day 4 +/- 1 day versus day 16 +/- 1 day of the chemotherapy cycle).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Heart Failure | — | UNRESOLVED | — |
| Mamma Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| influenza virus vaccine (influvac or vaxigrip) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- influenza vaccine day 4
- description
- influenza vaccine day 4 of chemotherapy
- interventionNames
- Biological: influenza virus vaccine (influvac or vaxigrip)
- type
- EXPERIMENTAL
- label
- influenza vaccine day 16
- description
- influenza vaccine day 16 of chemotherapy
- interventionNames
- Biological: influenza virus vaccine (influvac or vaxigrip)
- type
- ACTIVE_COMPARATOR
- label
- influenza vaccine
- description
- influenza vaccine in patients with heartfailure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with mamma carcinoma treated with FEC-containing triweekly chemotherapy at moment of vaccination * Patients with heart failure and therefore having an indication for the influenza vaccination * Age ≥ 18 years * Signing of informed consent Exclusion Criteria: * Fever at time of vaccination defined as a temperature of ≥ 38.5 °C. * Previous/known allergic reaction to any of the components of the vaccines given, for example hypersensitivity to egg protein * Thrombocytopenia (defined as \< 50 \* 109/L ) at moment of vaccination * Treatment with prednisolone on moment of vaccination.
References
Publications (0)
Data not yet available
No reference posted for this study.